Fig. 2From: The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson’s diseaseGlial activation associated with MPTP-induced dopaminergic degeneration. a Representative photomicrographs of IBA1- and GFAP-immunostained striatum of control mice administered with saline and MPTP-injected mice at the indicated time points after MPTP injections. b Representative photomicrographs of IBA1- and GFAP-immunostained substantia nigra pars compacta (SNpc) of control mice administered with saline and MPTP-injected mice at the indicated time points after MPTP injection. Scale bars: 100 μm (striatum), 200 um (SNpc) and 50 μm (insets)Back to article page